Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Mol Aspects Med. 2021 Aug 2;83:101007. doi: 10.1016/j.mam.2021.101007

Figure 6.

Figure 6.

Liposomal mRNA vaccine directly activates the STING pathway to treat melanoma. A) Heterocyclic lipid nanoparticles (LNPs) are composed of an ionizable lipidoid for STING activation and mRNA encoding for tumor antigens. Cellular uptake of the LNPs induces dendritic cell (DC) maturation and potentiates STING-mediated immunity against tumor cells via type I interferon (IFN) production. B,C) A18 LNPs with mRNA encoding the melanoma antigen TRP2 control tumor growth (B) and extend survival (C) in a B16F10 melanoma model. Reproduced with permission (Miao et al., 2019). Copyright 2019, Springer Nature.